Chip Stocks Lead Market Rally Amid Mixed Index Performance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 3 hours ago
0mins
Source: Fool
- Market Rally: On Monday, chip stocks led a market rally with the Nasdaq Composite rising 1.3% and the S&P 500 up 0.7%, while the Dow Jones Industrial Average slipped 0.1%, indicating a divergence in market performance.
- Broadcom and Apple Partnership: Broadcom's stock rose 4.4% after announcing its chip supply deal with Apple will extend through 2031, locking in custom silicon revenue for five more years, which is expected to positively impact multiple generations of iPhones.
- Strong AMD Performance: AMD shares surged 8% as Japanese autonomous driving startup Turing revealed that 10% of its AI training needs will utilize AMD graphics processors, reinforcing AMD's image as a budget-friendly option in self-driving technology.
- Microsoft Layoffs Impact: Microsoft announced 4,800 job cuts, leading to a 1.4% decline in its stock price, with analysts suggesting this reflects a strategic shift towards AI infrastructure spending, leaving investors uncertain about the long-term implications for the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GS
Wall Street analysts forecast GS stock price to fall
12 Analyst Rating
5 Buy
7 Hold
0 Sell
Moderate Buy
Current: 1019.610
Low
604.00
Averages
951.45
High
1100
Current: 1019.610
Low
604.00
Averages
951.45
High
1100
About GS
The Goldman Sachs Group, Inc. is a global financial institution that delivers a range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Its segments include Global Banking & Markets, Asset & Wealth Management and Platform Solutions. The Global Banking & Markets segment offers a range of services, including financing, advisory services, risk distribution, and hedging for its institutional and corporate clients. It facilitates client transactions and makes markets in fixed income, equity, currency and commodity products. The Asset & Wealth Management segment manages assets and offers investment products across all asset classes to a diverse set of clients. It also provides investing and wealth advisory solutions. The Platform Solutions segment includes consumer platforms, such as partnerships offering credit cards and point-of-sale financing, and transaction banking and other platform businesses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Analysis of Earnings from Locking in High CD Rates
- Current CD Rate Overview: As of July 5, 2026, the highest CD rate is 4.10% APY offered by Marcus by Goldman Sachs for a 14-month CD, indicating that in today's economic climate, longer-term CDs may yield lower rates than shorter-term options, affecting savers' strategies.
- Investment Earnings Calculation: For a $1,000 investment in a one-year CD at 1.52% APY, the end balance would be $1,015.20, illustrating the impact of compounding interest; choosing a 4% APY CD would increase the balance to $1,040.74, significantly enhancing interest earnings.
- Impact of Deposit Amount on Earnings: If the investment amount is raised to $10,000 with a 4% APY CD, the total balance at maturity would be $10,407.42, resulting in $407.42 in interest, emphasizing the positive correlation between deposit amounts and earnings.
- Diversity of CD Types: Beyond traditional CDs, options like Bump-up CDs, No-penalty CDs, and Jumbo CDs offer flexibility and potentially higher rates, although they may require sacrificing some interest, necessitating savers to choose based on their specific needs.
See More
Marvell Technology Stock Soars 129% Amid AI Growth Prospects
- Stock Surge: Marvell Technology's stock has surged 129% over the past three months, reflecting strong investor confidence in its growing prominence in the AI infrastructure sector, indicating a robust market outlook for future growth.
- Surge in Custom Chip Demand: The demand for Marvell's custom ASIC chips has skyrocketed due to their deployment in AI data centers, with projections suggesting that custom ASIC shipments could equal GPU sales next year, significantly boosting company revenues.
- Optical Networking Market Potential: The demand for optical networking products is vastly outpacing supply, with Goldman Sachs forecasting a 9x increase in sales over the next two years; Marvell's interconnect business is expected to grow by 70% this year, highlighting its critical role in AI data centers.
- Market Share Expectations: Marvell anticipates its total addressable market in data centers will reach $94 billion by 2028, aiming to capture 20% of this market, translating to over $19 billion in revenue, showcasing its strong potential in the rapidly expanding AI market.
See More
Marvell Technology Seizes Growth Opportunities in AI Infrastructure
- Surge in Custom Chip Demand: Marvell's custom ASIC chip demand has surged due to deployment in AI data centers, with shipments expected to match GPU sales next year, highlighting its strong growth potential in the AI infrastructure market.
- Optical Networking Supply Shortage: As optical networking becomes a key bottleneck in AI data centers, Marvell's sales of optical networking components are projected to increase ninefold in two years, driving rapid growth in its data center interconnect and switching businesses.
- Earnings Expectations Raised: Analysts project Marvell's earnings to grow by 43% this fiscal year, and the company anticipates its total addressable market for data centers to reach $94 billion by 2028, indicating sustained growth capability in the coming years.
- Market Share Gains: Marvell expects to capture 20% of the data center market by 2028, translating to $19 billion in revenue, more than tripling its fiscal 2026 data center revenue of $6.1 billion, underscoring its long-term growth potential in the AI infrastructure sector.
See More
SpaceX Set to Join Nasdaq-100 Amid Major Catalysts
- Record IPO Financing: SpaceX raised $85.7 billion in its initial public offering, marking the largest IPO in Wall Street history, which will provide substantial funding for future expansion and technological innovation.
- Inclusion in Nasdaq-100: SpaceX is set to officially join the Nasdaq-100 on July 7, a move that will trigger billions in passive investment inflows, potentially boosting its stock price and enhancing market recognition.
- Accelerated Inclusion Rules: Nasdaq Global Indexes amended its inclusion criteria on May 1, removing the low-float requirement and shortening the inclusion timeline to 15 trading days, which will expedite SpaceX's market integration and improve liquidity.
- Wall Street Analyst Coverage Release: The 25-day quiet period for SpaceX will end on July 7, with expectations that many participating underwriters will issue buy ratings and optimistic price targets, further driving investor interest and market confidence in its stock.
See More
Viking Therapeutics Faces Intense Competition in Obesity Drug Market
- Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the GLP-1 drug market at nearly $200 billion, highlighting significant opportunities for Viking Therapeutics in this sector.
- Investment Return Analysis: If VK2735 gains approval and captures 1% of the market, Viking's valuation could rise from $4.4 billion to $15 billion, allowing a $1,000 investment to grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Pressure: VK2735 must secure approval by 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have established strong market positions with effective treatments, presenting a high barrier for VK2735 to overcome.
- Clinical Trial Risks: VK2735's injectable form demonstrated a 14.7% weight loss in mid-stage trials, but its phase 3 trials won't conclude until 2027, and oral formulation trials are just beginning, creating uncertainty that could lead to investor losses of 60% to 80%.
See More
Viking Therapeutics Faces Market Challenges Ahead of VK2735 Launch
- Intense Market Competition: Viking Therapeutics' VK2735 is expected to hit the market within two years, yet it faces fierce competition from giants like Eli Lilly and Novo Nordisk, which dominate the obesity drug market, potentially hindering Viking's ability to capture market share.
- Clinical Trial Data: VK2735 demonstrated a weight loss of 14.7% in mid-stage trials, but even with promising data, Viking must exhibit significant advantages in efficacy, pricing, and tolerability to secure even 1% of the market.
- Investment Return Forecast: If VK2735 gains approval and captures 1% of the market, projected annual sales could reach $1.5 billion, leading to a potential company valuation of $15 billion based on a 10x price-to-sales ratio, suggesting a $1,000 investment could grow to $3,400, but dilution from new fundraising could reduce it to $2,500.
- Risk Assessment: In the best-case scenario, a $1,000 investment could grow to $10,000 by 2030, but given market competition and clinical trial uncertainties, the most likely outcome is closer to $2,500, highlighting the high-risk nature of investing in Viking.
See More
Analysis of Earnings from Locking in High CD Rates
- Current CD Rate Overview: As of July 5, 2026, the highest CD rate is 4.10% APY offered by Marcus by Goldman Sachs for a 14-month CD, indicating that in today's economic climate, longer-term CDs may yield lower rates than shorter-term options, affecting savers' strategies.
- Investment Earnings Calculation: For a $1,000 investment in a one-year CD at 1.52% APY, the end balance would be $1,015.20, illustrating the impact of compounding interest; choosing a 4% APY CD would increase the balance to $1,040.74, significantly enhancing interest earnings.
- Impact of Deposit Amount on Earnings: If the investment amount is raised to $10,000 with a 4% APY CD, the total balance at maturity would be $10,407.42, resulting in $407.42 in interest, emphasizing the positive correlation between deposit amounts and earnings.
- Diversity of CD Types: Beyond traditional CDs, options like Bump-up CDs, No-penalty CDs, and Jumbo CDs offer flexibility and potentially higher rates, although they may require sacrificing some interest, necessitating savers to choose based on their specific needs.
See More
Marvell Technology Stock Soars 129% Amid AI Growth Prospects
- Stock Surge: Marvell Technology's stock has surged 129% over the past three months, reflecting strong investor confidence in its growing prominence in the AI infrastructure sector, indicating a robust market outlook for future growth.
- Surge in Custom Chip Demand: The demand for Marvell's custom ASIC chips has skyrocketed due to their deployment in AI data centers, with projections suggesting that custom ASIC shipments could equal GPU sales next year, significantly boosting company revenues.
- Optical Networking Market Potential: The demand for optical networking products is vastly outpacing supply, with Goldman Sachs forecasting a 9x increase in sales over the next two years; Marvell's interconnect business is expected to grow by 70% this year, highlighting its critical role in AI data centers.
- Market Share Expectations: Marvell anticipates its total addressable market in data centers will reach $94 billion by 2028, aiming to capture 20% of this market, translating to over $19 billion in revenue, showcasing its strong potential in the rapidly expanding AI market.
See More
Marvell Technology Seizes Growth Opportunities in AI Infrastructure
- Surge in Custom Chip Demand: Marvell's custom ASIC chip demand has surged due to deployment in AI data centers, with shipments expected to match GPU sales next year, highlighting its strong growth potential in the AI infrastructure market.
- Optical Networking Supply Shortage: As optical networking becomes a key bottleneck in AI data centers, Marvell's sales of optical networking components are projected to increase ninefold in two years, driving rapid growth in its data center interconnect and switching businesses.
- Earnings Expectations Raised: Analysts project Marvell's earnings to grow by 43% this fiscal year, and the company anticipates its total addressable market for data centers to reach $94 billion by 2028, indicating sustained growth capability in the coming years.
- Market Share Gains: Marvell expects to capture 20% of the data center market by 2028, translating to $19 billion in revenue, more than tripling its fiscal 2026 data center revenue of $6.1 billion, underscoring its long-term growth potential in the AI infrastructure sector.
See More
SpaceX Set to Join Nasdaq-100 Amid Major Catalysts
- Record IPO Financing: SpaceX raised $85.7 billion in its initial public offering, marking the largest IPO in Wall Street history, which will provide substantial funding for future expansion and technological innovation.
- Inclusion in Nasdaq-100: SpaceX is set to officially join the Nasdaq-100 on July 7, a move that will trigger billions in passive investment inflows, potentially boosting its stock price and enhancing market recognition.
- Accelerated Inclusion Rules: Nasdaq Global Indexes amended its inclusion criteria on May 1, removing the low-float requirement and shortening the inclusion timeline to 15 trading days, which will expedite SpaceX's market integration and improve liquidity.
- Wall Street Analyst Coverage Release: The 25-day quiet period for SpaceX will end on July 7, with expectations that many participating underwriters will issue buy ratings and optimistic price targets, further driving investor interest and market confidence in its stock.
See More
Viking Therapeutics Faces Intense Competition in Obesity Drug Market
- Market Potential: According to Goldman Sachs, the weight loss drug market could reach $95 billion by 2030, while J.P. Morgan estimates the GLP-1 drug market at nearly $200 billion, highlighting significant opportunities for Viking Therapeutics in this sector.
- Investment Return Analysis: If VK2735 gains approval and captures 1% of the market, Viking's valuation could rise from $4.4 billion to $15 billion, allowing a $1,000 investment to grow to approximately $3,400, although risks of share dilution remain.
- Intense Competitive Pressure: VK2735 must secure approval by 2028 or 2029, by which time Eli Lilly and Novo Nordisk will have established strong market positions with effective treatments, presenting a high barrier for VK2735 to overcome.
- Clinical Trial Risks: VK2735's injectable form demonstrated a 14.7% weight loss in mid-stage trials, but its phase 3 trials won't conclude until 2027, and oral formulation trials are just beginning, creating uncertainty that could lead to investor losses of 60% to 80%.
See More
Viking Therapeutics Faces Market Challenges Ahead of VK2735 Launch
- Intense Market Competition: Viking Therapeutics' VK2735 is expected to hit the market within two years, yet it faces fierce competition from giants like Eli Lilly and Novo Nordisk, which dominate the obesity drug market, potentially hindering Viking's ability to capture market share.
- Clinical Trial Data: VK2735 demonstrated a weight loss of 14.7% in mid-stage trials, but even with promising data, Viking must exhibit significant advantages in efficacy, pricing, and tolerability to secure even 1% of the market.
- Investment Return Forecast: If VK2735 gains approval and captures 1% of the market, projected annual sales could reach $1.5 billion, leading to a potential company valuation of $15 billion based on a 10x price-to-sales ratio, suggesting a $1,000 investment could grow to $3,400, but dilution from new fundraising could reduce it to $2,500.
- Risk Assessment: In the best-case scenario, a $1,000 investment could grow to $10,000 by 2030, but given market competition and clinical trial uncertainties, the most likely outcome is closer to $2,500, highlighting the high-risk nature of investing in Viking.
See More
